nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—CYP2D6—Hydroxyurea—psoriasis	0.168	0.441	CbGbCtD
Methylnaltrexone—CYP2D6—Cholecalciferol—psoriasis	0.102	0.267	CbGbCtD
Methylnaltrexone—CYP2D6—Cyclosporine—psoriasis	0.0668	0.176	CbGbCtD
Methylnaltrexone—CYP2D6—Dexamethasone—psoriasis	0.044	0.116	CbGbCtD
Methylnaltrexone—Stinging—Calcipotriol—psoriasis	0.0362	0.0584	CcSEcCtD
Methylnaltrexone—Stinging—Tazarotene—psoriasis	0.0267	0.043	CcSEcCtD
Methylnaltrexone—Stinging—Clobetasol propionate—psoriasis	0.0226	0.0365	CcSEcCtD
Methylnaltrexone—Redness—Methoxsalen—psoriasis	0.0193	0.0312	CcSEcCtD
Methylnaltrexone—Redness—Calcitriol—psoriasis	0.0172	0.0278	CcSEcCtD
Methylnaltrexone—Redness—Acitretin—psoriasis	0.0153	0.0247	CcSEcCtD
Methylnaltrexone—Erythema—Calcipotriol—psoriasis	0.0128	0.0207	CcSEcCtD
Methylnaltrexone—Erythema—Tazarotene—psoriasis	0.00945	0.0152	CcSEcCtD
Methylnaltrexone—Pain—Calcipotriol—psoriasis	0.00894	0.0144	CcSEcCtD
Methylnaltrexone—Erythema—Clobetasol propionate—psoriasis	0.00801	0.0129	CcSEcCtD
Methylnaltrexone—Oedema—Tazarotene—psoriasis	0.00771	0.0124	CcSEcCtD
Methylnaltrexone—Redness—Hydrocortisone—psoriasis	0.00724	0.0117	CcSEcCtD
Methylnaltrexone—Erythema—Fluocinonide—psoriasis	0.00722	0.0117	CcSEcCtD
Methylnaltrexone—Stinging—Cyclosporine—psoriasis	0.00679	0.011	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Clobetasol propionate—psoriasis	0.00677	0.0109	CcSEcCtD
Methylnaltrexone—Pain—Tazarotene—psoriasis	0.00659	0.0106	CcSEcCtD
Methylnaltrexone—Skin disorder—Clobetasol propionate—psoriasis	0.00635	0.0102	CcSEcCtD
Methylnaltrexone—Stinging—Prednisolone—psoriasis	0.00618	0.00997	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Fluocinonide—psoriasis	0.00611	0.00985	CcSEcCtD
Methylnaltrexone—Stinging—Hydrocortisone—psoriasis	0.00604	0.00974	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Fluocinonide—psoriasis	0.00578	0.00933	CcSEcCtD
Methylnaltrexone—Skin disorder—Fluocinonide—psoriasis	0.00573	0.00924	CcSEcCtD
Methylnaltrexone—Erythema—Methoxsalen—psoriasis	0.0057	0.0092	CcSEcCtD
Methylnaltrexone—Stinging—Triamcinolone—psoriasis	0.00568	0.00917	CcSEcCtD
Methylnaltrexone—Pain—Clobetasol propionate—psoriasis	0.00559	0.00902	CcSEcCtD
Methylnaltrexone—Injection site reaction—Mycophenolate mofetil—psoriasis	0.00534	0.00861	CcSEcCtD
Methylnaltrexone—Stinging—Dexamethasone—psoriasis	0.00516	0.00832	CcSEcCtD
Methylnaltrexone—Stinging—Betamethasone—psoriasis	0.00516	0.00832	CcSEcCtD
Methylnaltrexone—Pain—Beclomethasone—psoriasis	0.00509	0.00821	CcSEcCtD
Methylnaltrexone—Erythema—Calcitriol—psoriasis	0.00508	0.0082	CcSEcCtD
Methylnaltrexone—Pain—Fluocinonide—psoriasis	0.00504	0.00813	CcSEcCtD
Methylnaltrexone—Oedema—Methoxsalen—psoriasis	0.00465	0.00751	CcSEcCtD
Methylnaltrexone—Erythema—Acitretin—psoriasis	0.00452	0.00729	CcSEcCtD
Methylnaltrexone—Skin disorder—Methoxsalen—psoriasis	0.00452	0.00729	CcSEcCtD
Methylnaltrexone—Erythema—Fluocinolone Acetonide—psoriasis	0.00451	0.00727	CcSEcCtD
Methylnaltrexone—Skin disorder—Calcitriol—psoriasis	0.00403	0.0065	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Methoxsalen—psoriasis	0.00402	0.00648	CcSEcCtD
Methylnaltrexone—Dizziness—Beclomethasone—psoriasis	0.00393	0.00635	CcSEcCtD
Methylnaltrexone—Dizziness—Fluocinonide—psoriasis	0.0039	0.00629	CcSEcCtD
Methylnaltrexone—Oedema—Acitretin—psoriasis	0.00369	0.00595	CcSEcCtD
Methylnaltrexone—Oedema—Fluocinolone Acetonide—psoriasis	0.00368	0.00594	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Fluocinolone Acetonide—psoriasis	0.00361	0.00582	CcSEcCtD
Methylnaltrexone—Skin disorder—Acitretin—psoriasis	0.00358	0.00578	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Acitretin—psoriasis	0.00357	0.00576	CcSEcCtD
Methylnaltrexone—Erythema—Hydroxyurea—psoriasis	0.00355	0.00573	CcSEcCtD
Methylnaltrexone—Pain—Calcitriol—psoriasis	0.00355	0.00572	CcSEcCtD
Methylnaltrexone—Nausea—Beclomethasone—psoriasis	0.00353	0.0057	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Calcitriol—psoriasis	0.00339	0.00547	CcSEcCtD
Methylnaltrexone—Abdominal pain—Calcitriol—psoriasis	0.00328	0.00529	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Acitretin—psoriasis	0.00319	0.00514	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Fluocinolone Acetonide—psoriasis	0.00318	0.00513	CcSEcCtD
Methylnaltrexone—Pain—Acitretin—psoriasis	0.00316	0.00509	CcSEcCtD
Methylnaltrexone—Pain—Fluocinolone Acetonide—psoriasis	0.00315	0.00508	CcSEcCtD
Methylnaltrexone—Dizziness—Methoxsalen—psoriasis	0.00308	0.00496	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Acitretin—psoriasis	0.00302	0.00487	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—psoriasis	0.003	0.00484	CcSEcCtD
Methylnaltrexone—Flatulence—Mycophenolic acid—psoriasis	0.00293	0.00473	CcSEcCtD
Methylnaltrexone—Abdominal pain—Acitretin—psoriasis	0.00292	0.00471	CcSEcCtD
Methylnaltrexone—Oedema—Hydroxyurea—psoriasis	0.0029	0.00467	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Hydroxyurea—psoriasis	0.00284	0.00458	CcSEcCtD
Methylnaltrexone—Diarrhoea—Calcitriol—psoriasis	0.00284	0.00458	CcSEcCtD
Methylnaltrexone—Skin disorder—Hydroxyurea—psoriasis	0.00281	0.00454	CcSEcCtD
Methylnaltrexone—Nausea—Methoxsalen—psoriasis	0.00276	0.00446	CcSEcCtD
Methylnaltrexone—Vomiting—Calcitriol—psoriasis	0.00264	0.00425	CcSEcCtD
Methylnaltrexone—Diarrhoea—Acitretin—psoriasis	0.00252	0.00407	CcSEcCtD
Methylnaltrexone—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.00252	0.00406	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.00251	0.00406	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.0025	0.00404	CcSEcCtD
Methylnaltrexone—Pain—Hydroxyurea—psoriasis	0.00248	0.004	CcSEcCtD
Methylnaltrexone—Nausea—Calcitriol—psoriasis	0.00246	0.00397	CcSEcCtD
Methylnaltrexone—Dizziness—Acitretin—psoriasis	0.00244	0.00394	CcSEcCtD
Methylnaltrexone—Dizziness—Fluocinolone Acetonide—psoriasis	0.00243	0.00393	CcSEcCtD
Methylnaltrexone—Oedema—Mycophenolic acid—psoriasis	0.00243	0.00391	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Mycophenolic acid—psoriasis	0.00238	0.00384	CcSEcCtD
Methylnaltrexone—Flatulence—Cyclosporine—psoriasis	0.00237	0.00382	CcSEcCtD
Methylnaltrexone—Skin disorder—Mycophenolic acid—psoriasis	0.00236	0.0038	CcSEcCtD
Methylnaltrexone—Vomiting—Acitretin—psoriasis	0.00235	0.00379	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Mycophenolic acid—psoriasis	0.00235	0.00378	CcSEcCtD
Methylnaltrexone—Vomiting—Fluocinolone Acetonide—psoriasis	0.00234	0.00377	CcSEcCtD
Methylnaltrexone—Flatulence—Mycophenolate mofetil—psoriasis	0.00231	0.00373	CcSEcCtD
Methylnaltrexone—Nausea—Acitretin—psoriasis	0.00219	0.00354	CcSEcCtD
Methylnaltrexone—Erythema—Prednisolone—psoriasis	0.00219	0.00353	CcSEcCtD
Methylnaltrexone—Nausea—Fluocinolone Acetonide—psoriasis	0.00219	0.00353	CcSEcCtD
Methylnaltrexone—Erythema—Hydrocortisone—psoriasis	0.00214	0.00345	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.00209	0.00338	CcSEcCtD
Methylnaltrexone—Pain—Mycophenolic acid—psoriasis	0.00207	0.00335	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.00203	0.00328	CcSEcCtD
Methylnaltrexone—Erythema—Triamcinolone—psoriasis	0.00201	0.00325	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.00198	0.0032	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.00198	0.0032	CcSEcCtD
Methylnaltrexone—Diarrhoea—Hydroxyurea—psoriasis	0.00198	0.0032	CcSEcCtD
Methylnaltrexone—Oedema—Cyclosporine—psoriasis	0.00196	0.00317	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Cyclosporine—psoriasis	0.00192	0.00311	CcSEcCtD
Methylnaltrexone—Abdominal pain—Mycophenolic acid—psoriasis	0.00192	0.00309	CcSEcCtD
Methylnaltrexone—Dizziness—Hydroxyurea—psoriasis	0.00192	0.00309	CcSEcCtD
Methylnaltrexone—Oedema—Mycophenolate mofetil—psoriasis	0.00191	0.00309	CcSEcCtD
Methylnaltrexone—Skin disorder—Cyclosporine—psoriasis	0.00191	0.00308	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Cyclosporine—psoriasis	0.0019	0.00306	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.00188	0.00303	CcSEcCtD
Methylnaltrexone—Skin disorder—Mycophenolate mofetil—psoriasis	0.00186	0.003	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.00185	0.00299	CcSEcCtD
Methylnaltrexone—Vomiting—Hydroxyurea—psoriasis	0.00184	0.00297	CcSEcCtD
Methylnaltrexone—Erythema—Betamethasone—psoriasis	0.00183	0.00295	CcSEcCtD
Methylnaltrexone—Erythema—Dexamethasone—psoriasis	0.00183	0.00295	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.00181	0.00292	CcSEcCtD
Methylnaltrexone—Oedema—Prednisolone—psoriasis	0.00179	0.00288	CcSEcCtD
Methylnaltrexone—Oedema—Hydrocortisone—psoriasis	0.00174	0.00281	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Prednisolone—psoriasis	0.00173	0.00279	CcSEcCtD
Methylnaltrexone—Nausea—Hydroxyurea—psoriasis	0.00172	0.00278	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Hydrocortisone—psoriasis	0.00171	0.00276	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Cyclosporine—psoriasis	0.00169	0.00273	CcSEcCtD
Methylnaltrexone—Skin disorder—Hydrocortisone—psoriasis	0.00169	0.00273	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Hydrocortisone—psoriasis	0.00169	0.00272	CcSEcCtD
Methylnaltrexone—Pain—Cyclosporine—psoriasis	0.00168	0.00271	CcSEcCtD
Methylnaltrexone—Diarrhoea—Mycophenolic acid—psoriasis	0.00166	0.00268	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.00165	0.00267	CcSEcCtD
Methylnaltrexone—Oedema—Triamcinolone—psoriasis	0.00164	0.00265	CcSEcCtD
Methylnaltrexone—Pain—Mycophenolate mofetil—psoriasis	0.00164	0.00264	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Cyclosporine—psoriasis	0.00161	0.00259	CcSEcCtD
Methylnaltrexone—Dizziness—Mycophenolic acid—psoriasis	0.0016	0.00259	CcSEcCtD
Methylnaltrexone—Erythema—Prednisone—psoriasis	0.00159	0.00257	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Triamcinolone—psoriasis	0.00159	0.00256	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.00157	0.00253	CcSEcCtD
Methylnaltrexone—Abdominal pain—Cyclosporine—psoriasis	0.00155	0.0025	CcSEcCtD
Methylnaltrexone—Vomiting—Mycophenolic acid—psoriasis	0.00154	0.00249	CcSEcCtD
Methylnaltrexone—Pain—Prednisolone—psoriasis	0.00153	0.00246	CcSEcCtD
Methylnaltrexone—Abdominal pain—Mycophenolate mofetil—psoriasis	0.00151	0.00244	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.00151	0.00243	CcSEcCtD
Methylnaltrexone—Pain—Hydrocortisone—psoriasis	0.00149	0.00241	CcSEcCtD
Methylnaltrexone—Oedema—Dexamethasone—psoriasis	0.00149	0.0024	CcSEcCtD
Methylnaltrexone—Oedema—Betamethasone—psoriasis	0.00149	0.0024	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Dexamethasone—psoriasis	0.00146	0.00236	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Betamethasone—psoriasis	0.00146	0.00236	CcSEcCtD
Methylnaltrexone—Nausea—Mycophenolic acid—psoriasis	0.00144	0.00233	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Betamethasone—psoriasis	0.00144	0.00232	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Dexamethasone—psoriasis	0.00144	0.00232	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Hydrocortisone—psoriasis	0.00143	0.0023	CcSEcCtD
Methylnaltrexone—Pain—Triamcinolone—psoriasis	0.0014	0.00227	CcSEcCtD
Methylnaltrexone—Abdominal pain—Hydrocortisone—psoriasis	0.00138	0.00222	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.00134	0.00217	CcSEcCtD
Methylnaltrexone—Diarrhoea—Cyclosporine—psoriasis	0.00134	0.00217	CcSEcCtD
Methylnaltrexone—Erythema—Methotrexate—psoriasis	0.00133	0.00214	CcSEcCtD
Methylnaltrexone—Diarrhoea—Mycophenolate mofetil—psoriasis	0.00131	0.00211	CcSEcCtD
Methylnaltrexone—Dizziness—Cyclosporine—psoriasis	0.0013	0.00209	CcSEcCtD
Methylnaltrexone—Oedema—Prednisone—psoriasis	0.0013	0.00209	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Dexamethasone—psoriasis	0.00129	0.00208	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Betamethasone—psoriasis	0.00129	0.00208	CcSEcCtD
Methylnaltrexone—Pain—Dexamethasone—psoriasis	0.00127	0.00206	CcSEcCtD
Methylnaltrexone—Pain—Betamethasone—psoriasis	0.00127	0.00206	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Prednisone—psoriasis	0.00127	0.00205	CcSEcCtD
Methylnaltrexone—Dizziness—Mycophenolate mofetil—psoriasis	0.00127	0.00204	CcSEcCtD
Methylnaltrexone—Skin disorder—Prednisone—psoriasis	0.00126	0.00203	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Prednisone—psoriasis	0.00125	0.00202	CcSEcCtD
Methylnaltrexone—Vomiting—Cyclosporine—psoriasis	0.00125	0.00201	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Dexamethasone—psoriasis	0.00122	0.00197	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Betamethasone—psoriasis	0.00122	0.00197	CcSEcCtD
Methylnaltrexone—Vomiting—Mycophenolate mofetil—psoriasis	0.00122	0.00196	CcSEcCtD
Methylnaltrexone—Diarrhoea—Hydrocortisone—psoriasis	0.00119	0.00193	CcSEcCtD
Methylnaltrexone—Dizziness—Prednisolone—psoriasis	0.00118	0.00191	CcSEcCtD
Methylnaltrexone—Abdominal pain—Betamethasone—psoriasis	0.00118	0.0019	CcSEcCtD
Methylnaltrexone—Abdominal pain—Dexamethasone—psoriasis	0.00118	0.0019	CcSEcCtD
Methylnaltrexone—Nausea—Cyclosporine—psoriasis	0.00117	0.00188	CcSEcCtD
Methylnaltrexone—Dizziness—Hydrocortisone—psoriasis	0.00115	0.00186	CcSEcCtD
Methylnaltrexone—Nausea—Mycophenolate mofetil—psoriasis	0.00114	0.00183	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.00112	0.00181	CcSEcCtD
Methylnaltrexone—Vomiting—Hydrocortisone—psoriasis	0.00111	0.00179	CcSEcCtD
Methylnaltrexone—Dizziness—Triamcinolone—psoriasis	0.00109	0.00175	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Methotrexate—psoriasis	0.00106	0.00172	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Prednisone—psoriasis	0.00106	0.00171	CcSEcCtD
Methylnaltrexone—Nausea—Prednisolone—psoriasis	0.00106	0.00171	CcSEcCtD
Methylnaltrexone—Skin disorder—Methotrexate—psoriasis	0.00105	0.0017	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Methotrexate—psoriasis	0.00105	0.00169	CcSEcCtD
Methylnaltrexone—Vomiting—Triamcinolone—psoriasis	0.00104	0.00168	CcSEcCtD
Methylnaltrexone—Nausea—Hydrocortisone—psoriasis	0.00104	0.00167	CcSEcCtD
Methylnaltrexone—Abdominal pain—Prednisone—psoriasis	0.00103	0.00166	CcSEcCtD
Methylnaltrexone—Diarrhoea—Betamethasone—psoriasis	0.00102	0.00165	CcSEcCtD
Methylnaltrexone—Diarrhoea—Dexamethasone—psoriasis	0.00102	0.00165	CcSEcCtD
Methylnaltrexone—Dizziness—Betamethasone—psoriasis	0.000986	0.00159	CcSEcCtD
Methylnaltrexone—Dizziness—Dexamethasone—psoriasis	0.000986	0.00159	CcSEcCtD
Methylnaltrexone—Nausea—Triamcinolone—psoriasis	0.000976	0.00157	CcSEcCtD
Methylnaltrexone—Vomiting—Dexamethasone—psoriasis	0.000948	0.00153	CcSEcCtD
Methylnaltrexone—Vomiting—Betamethasone—psoriasis	0.000948	0.00153	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Methotrexate—psoriasis	0.000936	0.00151	CcSEcCtD
Methylnaltrexone—Pain—Methotrexate—psoriasis	0.000928	0.0015	CcSEcCtD
Methylnaltrexone—Diarrhoea—Prednisone—psoriasis	0.000888	0.00143	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Methotrexate—psoriasis	0.000887	0.00143	CcSEcCtD
Methylnaltrexone—Nausea—Betamethasone—psoriasis	0.000885	0.00143	CcSEcCtD
Methylnaltrexone—Nausea—Dexamethasone—psoriasis	0.000885	0.00143	CcSEcCtD
Methylnaltrexone—Dizziness—Prednisone—psoriasis	0.000858	0.00138	CcSEcCtD
Methylnaltrexone—Abdominal pain—Methotrexate—psoriasis	0.000857	0.00138	CcSEcCtD
Methylnaltrexone—Vomiting—Prednisone—psoriasis	0.000825	0.00133	CcSEcCtD
Methylnaltrexone—Nausea—Prednisone—psoriasis	0.000771	0.00124	CcSEcCtD
Methylnaltrexone—Diarrhoea—Methotrexate—psoriasis	0.000742	0.0012	CcSEcCtD
Methylnaltrexone—Dizziness—Methotrexate—psoriasis	0.000717	0.00116	CcSEcCtD
Methylnaltrexone—Vomiting—Methotrexate—psoriasis	0.00069	0.00111	CcSEcCtD
Methylnaltrexone—Nausea—Methotrexate—psoriasis	0.000644	0.00104	CcSEcCtD
